The gastrointestinal microbiota is a complex ecosystem with each human individual hosting at least 160 different bacterial strains. Our understanding of its role is rapidly expanding as a result of the molecular microbiological techniques that can accurately characterise its composition and ‘omics’ technologies that measure its metabolic activity. Since 1995, extensive research has investigated the prebiotic concept, which describes how supplementation of some non-digestible oligosaccharides can stimulate the growth and/or activity of specific genera including bifidobacteria. However, the vast majority of studies are in healthy human subjects, with few undertaken in patients with disorders relevant to clinical nutrition. Marked alterations of the luminal microbiota have been demonstrated in patients with digestive disorders, highlighting mechanisms through which they might be involved in their pathogenesis, including higher clostridia in patients who develop diarrhoea during enteral nutrition and the influence of bifidobacteria on intestinal dendritic cell phenotype in Crohn’s disease. The impact of prebiotics on the intestinal microbiota of healthy people has not been consistently replicated in patients with digestive disorders. For example, a number of studies show that inulin/oligofructose do not increase bifidobacteria in enteral nutrition and Crohn’s disease. Indeed, in Crohn’s disease and irritable bowel syndrome there is evidence that some prebiotics in high doses worsen functional symptoms. Unlike healthy human subjects, patients experience a number of issues that may alter their gastrointestinal microbiota (disease, antibiotics and inflammation) and the use of microbiota modifying therapies, such as prebiotics, do not always elicit the same effects in patients as they do in healthy people.
However, these required the target organisms to be known, isolated and sequenced and for specific probes and primers to be developed and validated. Recently, approaches to sequencing the microbiota have been developed that overcome these problems, allowing the whole GI microbiome to be identified and characterised.

One of the biggest advances thus far has been the comprehensive metagenomic sequencing of the GI microbiota by the MetaHIT Consortium (Metagenomics of the Human Intestinal Tract, http://www.metahit.eu/).

In a study of 124 individuals, the results demonstrated that any of 1000–1150 different bacterial species could populate the human GI tract, with each individual harbouring approximately 160 different species. Given these large numbers there is great potential for inter-individual diversity in microbiota composition. Despite this, considerable stability was found between individuals for certain species. For example, a core eighteen species were found in all subjects, fifty-seven were found in 90% and seventy-five species were found in 50%.

In a further analysis of the microbiota from across four countries (including those from MetaHIT and the Human Microbiome Project) it was found that bacteria cluster within individuals.

The GI microbiota sequences were shown to fit into three distinct clusters termed ‘enterotypes’, characterised by the predominance of Bacteroides (enterotype 1), Prevotella (enterotype 2) and Ruminococcus (enterotype 3). The abundance of these main contributors correlated positively or negatively with other genera. For example, human subjects with enterotype 1 had high levels of Bacteroides, the numbers of which were positively correlated with Parabacteroides and Clostridiales but negatively correlated with Lactobacillus, indicating a propensity for these to co-exist or avoid other species, respectively. Taken together, these findings describe a microbial ecosystem whose structure is determined, at least in part, by the abundance of species that together contribute to a limited number of preferred compositions. The association between enterotype, optimal health and disease risk is yet to be fully examined.

The composition of the GI microbiota is influenced by a range of factors including ageing and diet. The microbiota in older people has been shown to be considerably different in terms of diversity and abundance when compared with younger adults, with a recent large study showing older people had higher Bacteroides and Clostridia cluster IV (including Faecalibacterium prausnitzii). The impact of diet on the GI microbiota in healthy people has been recognised for well over a century, following the description of differences in bifidobacteria between breastfed and formula-fed infants.

However, only recently has the impact on the GI microbiota of nutrients and food components been explored in depth. Habitual long-term diet has recently been shown to strongly associate with enterotype, in particular an association between protein/animal fat and Bacteroides (enterotype 1) and between carbohydrate and Prevotella (enterotype 2). In terms of dietary alterations, acute feeding studies have identified that altering fat and non-starch polysaccharide intakes has a considerable impact on the microbiota, although they do not result in switching between enterotypes, indicating considerable stability of the latter following dietary change.

Studies in gnotobiotic mice undergoing manipulation of dietary protein, fat and carbohydrate intake have found that dietary changes account for a majority of the alterations occurring in the microbiota. Extensive research has demonstrated a role for specific dietary carbohydrates in modifying the microbiota, first described as the prebiotic concept in 1995.

### Prebiotic carbohydrates

Prebiotics are non-digestible, fermentable food components that result in the selective stimulation of growth and/or activity of one or a limited number of microbial genera/species in the gut microbiota that confer health benefits to the host. The most commonly used prebiotics are inulin-type fructans such as inulin, oligofructose, fructooligosaccharides and galacto-oligosaccharides (GOS) such as stachyose and raffinose.

The essential characteristics of a prebiotic are their resistance to digestion, fermentability and selectivity in promoting the growth or activity of beneficial bacteria. Resistance to small-intestinal digestion is the result of human subjects lacking enzymes that hydrolyse the polymer bonds. This allows the prebiotic to reach the colon intact and undergo fermentation, but only by a limited number of genera/species. For example, some bacteria have ‘fructan utilisation locus’ genes that enable them to acquire and ferment inulin-type fructans. Recent murine feeding studies have shown that the in vivo functionality of the ‘fructan utilisation locus’ was strongly predictive of the ability of a strain to grow when animals were fed these prebiotics. Proliferation of specific genera/species is thought to be driven by competitive selection resulting from the ability of these to access the carbon source of prebiotics.

Many prebiotic carbohydrates are present in the normal diet. For example, inulin-type fructans are found in relatively large amounts in chicory root (35.7–47.6 g/100 g), Jerusalem artichoke (16–20 g/100 g) and garlic (9–16 g/100 g), but they are also present in smaller amounts in cereals such as wheat (1–4 g/100 g). However, as wheat is a staple in many western countries, dietary surveys show that it is the major contributor to fructan intake in the United Kingdom (66%) and the United States (69%). Bread contains only a small amount of fructan (0.61–1.94 g/100 g depending upon the recipe and cereal source), but as the most widely consumed food item in the United Kingdom it makes a large contribution to inulin intake. Meanwhile, GOS such as stachyose and raffinose are widely contained and consumed within pulses.

In the first key human study to demonstrate the prebiotic effect, eight healthy volunteers consuming a controlled diet were supplemented with 15 g/d oligofructose or inulin, both of which resulted in almost a 1 log10 increase in luminal bifidobacteria, which then returned to baseline following withdrawal of the prebiotic. The prebiotic properties of such supplements have been confirmed in a series of animal and human studies, and have been...
Enteral nutrition

EN is a common method of artificial nutritional support for patients who are unable to achieve their nutritional requirements through oral diet. Alterations in stool output can occur which result in the diagnosis of diarrhoea, which has a reported prevalence ranging from 2 to 95% of patients. The wide range is the result of differences in the patient groups and the definition of diarrhoea used. There are at least three different definitions of diarrhoea used in the literature regarding EN (23). Meanwhile, in clinical practice, doctors, dietitians, nurses and patients vary in the importance they assign to different stool characteristics when defining diarrhoea during EN (24,25), highlighting the importance of standardised, valid and reliable approaches to recording and defining it (26,27).

Diarrhoea can be a problematic complication of EN, leading to dehydration and a requirement for intravenous fluid support. Despite this, it is not uncommon for some health professionals to reduce or cease EN during episodes of diarrhoea (25), a practice that might in part explain the association between high stool output and poorer delivery of enteral formula (28). Diarrhoea also increases the risk of faecal incontinence, which patients rate as the most unpleasant aspect of diarrhoea (25), and which of course can contribute to infection of surgical or pressure wounds.

A number of factors implicate a role for the GI microbiota in pathogenesis of diarrhoea during EN, including antibiotic prescription, enteropathogenic colonisation and abnormal colonic responses (29). The prevalence of diarrhoea during EN is higher in patients prescribed antibiotics (30) which is thought to relate to their effect on the GI microbiota and on the SCFA produced during fermentation (31). Clostridium difficile colonisation can occur during EN, with one case–control study demonstrating a 9-fold greater risk of C. difficile-associated diarrhoea in patients receiving EN (32). During intra-gastric infusion of enteral formula, water is actively secreted into the ascending colon, which might contribute to the pathogenesis of diarrhoea, but this fluid secretion is prevented by caecal infusion of SCFA (33).

Given their potential role in the pathogenesis of diarrhoea during EN, studies have investigated the composition of the GI microbiota in such patients. In a cohort study of twenty patients receiving standard (fibre-free) enteral formula, there was marked instability of the luminal microbiota and those who developed diarrhoea had higher clostridia and lower bifidobacteria (34). The origin of these alterations is unclear. Consumption of standard, fibre-free enteral formula by healthy subjects has been shown to result in reduction in total bacteria (35) and in Faecalibacterium prausnitzii (36), a major producer of the SCFA butyrate that stimulates colonic water absorption.

Fortifying enteral formulas with prebiotics and fibres has been proposed as a method to increase bifidobacteria to assist in colonisation resistance and to increase SCFA production to stimulate colonic water absorption (37,38). Indeed, a number of studies have demonstrated that enteral formulas fortified with fibre and prebiotics increase luminal bifidobacteria and SCFA when consumed by healthy people (35,38). In addition, other benefits such as appetite suppression, which may be important in patients receiving exclusive EN, have also been demonstrated (39).

Despite these promising effects in healthy subjects, application in the clinical setting has yielded disappointing results. Although trials have been limited in design and sample size, some show little impact on bifidobacteria (40,41) or SCFA concentrations (42) (Table 1). Two clinical trials in patients receiving long-term EN in the community showed either no impact (40) or a trend towards an increase (43) in bifidobacteria during feeding with formulae supplemented with fibre and prebiotics. Meanwhile, in hospitalised patients, a non-randomised trial found no differences in bifidobacteria between those receiving a standard formula or one supplemented with a mix of fibre, inulin and oligofructose (47). More recently, the results of a randomised controlled trial indicated that compared with normal levels of fibre and prebiotics, additional inulin/oligofructose had no impact on bifidobacteria and actually lowered F. prausnitzii in patients receiving EN on the intensive care unit (44) (Table 1).

Given the disappointing results for use of prebiotics in patients receiving EN, a contrasting approach is the use of probiotics, some strains of which are efficacious in the prevention of C. difficile-associated diarrhoea (45,46). At least six randomised controlled trials of probiotics in prevention or treatment of diarrhoea in EN have been undertaken (47), but only two have shown a beneficial effect in preventing diarrhoea, for Saccharomyces boulardii (48) and VSL#3 (49) both in the intensive care setting. Some researchers and clinicians have raised concerns about the safety of probiotics in such patient groups. However, despite a systematic review identifying case reports of adverse events in thirty-two patients receiving EN and probiotics, the vast majority of trials showed either no effect, or a positive effect, on outcomes related to safety (e.g. mortality and infections) (50).

Crohn’s disease

Crohn’s disease is a chronic relapsing and remitting inflammatory bowel disease characterised by discontinuous transmural inflammation, ulceration and strictureing
### Table 1. Clinical trials of prebiotic supplementation in patients receiving enteral nutrition

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study details</th>
<th>Intervention formulas</th>
<th>Microbiota findings</th>
<th>SCFA findings</th>
<th>Clinical findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sobotka et al.(42)</td>
<td>Non-randomised, cross-over trial Nine patients receiving EN in hospital One-week intervention period</td>
<td>(1) Standard (2) Standard plus inulin (15 g/l)</td>
<td>Not measured</td>
<td>No differences between groups in any SCFA</td>
<td>No differences between groups in stool frequency or consistency Increase in number of days with flatulence in inulin group</td>
</tr>
<tr>
<td>Schneider et al.(40)</td>
<td>Randomised, cross-over trial Fifteen patients receiving ong term EN Two-week intervention period</td>
<td>(1) Standard (2) Mixed fibre (15 g/l) including oligofructose/inulin (3.5 g/l)</td>
<td>Higher total numbers of bacteria in the prebiotic group compared with standard. No differences in any microbiota measured (including bifidobacteria)</td>
<td>Higher total SCFA and butyrate in the fibre/prebiotic group compared with standard. No difference in other SCFA</td>
<td>No differences between groups in stool frequency</td>
</tr>
<tr>
<td>Wierdsma et al.(43)</td>
<td>Randomised, double-blind trial Sixteen patients receiving home EN Six-week intervention period</td>
<td>(1) Standard (2) Mixed fibre (10.6 g/l), plus oligofructose/inulin (7 g/l)</td>
<td>'Nearly significantly' higher bifidobacteria in the prebiotic group ($P = 0.056$)</td>
<td>Not measured</td>
<td>No differences between groups in stool frequency, consistency or abdominal complaints</td>
</tr>
<tr>
<td>Majid et al.(41)</td>
<td>Non-randomised trial Forty-one patients receiving EN in hospital Two-week intervention period</td>
<td>(1) Standard (2) Mixed fibre (15 g/l) including oligofructose/inulin (4.5 g/l)</td>
<td>No difference between groups in any microbiota measured (including bifidobacteria)</td>
<td>Higher butyrate in prebiotic group. No difference in any other SCFA</td>
<td>Not measured</td>
</tr>
<tr>
<td>Majid et al.(44)</td>
<td>Randomised, placebo-controlled Twenty-two patients receiving EN on ICU One-two-week intervention period</td>
<td>(1) Mixed fibre (15 g/l), including oligofructose/inulin (4.5 g/l) plus placebo (7 g/d) (2) Mixed fibre (15 g/l), including oligofructose/inulin (4.5 g/l), plus additional oligofructose/inulin (7 g/d)</td>
<td>Lower <em>F. prausnitzii</em> in the additional prebiotic group. No differences in any other microbiota measured (including bifidobacteria)</td>
<td>No difference between groups in any SCFA</td>
<td>No difference between groups in stool frequency, stool score or prevalence of diarrhoea</td>
</tr>
</tbody>
</table>

EN, enteral nutrition; ICU, intensive care unit.
anywhere in the GI tract. In Europe, the incidence ranges from 0.7 to 9.8 cases per 100,000 person-years.\(^{(51)}\) Symptoms include diarrhoea, faecal urgency, severe abdominal pain and rectal bleeding and complications such as fistula may occur. These symptoms can have a profound impact, with evidence of impairments in nutritional status\(^{(52)}\), body weight, social functioning\(^{(53)}\) and quality of life\(^{(54)}\).

The primary treatment approach in Crohn’s disease is usually drug therapy, including steroids (e.g. prednisolone), immunosuppressants (e.g. azathioprine) and biological drugs such as monoclonal antibodies (e.g. infliximab)\(^{(55)}\). Nutritional approaches to treat Crohn’s disease are available, the most notable being exclusive EN, which in clinical trials induces remission in 60–85% of patients\(^{(56)}\). However, there are some drawbacks. Studies show that EN is less effective a treatment for Crohn’s disease than steroids\(^{(56)}\), while in clinical practice, palatability and poor compliance can be problematic\(^{(57)}\) and as a result it is mostly commonly used as a steroid-sparing treatment in children. There is considerable evidence that the GI microbiota are directly involved in the pathogenesis of Crohn’s disease, and therefore nutritional treatments such as prebiotics which might be a safe and effective treatment strategy, are an attractive option.

Crohn’s disease results from a heightened mucosal immune response to the GI microbiota in genetically susceptible individuals. Broadly speaking, this results from alterations in the balance of pro-inflammatory (e.g. IL-1, IL-6, IL-12 and interferon-\(\gamma\)) and immuno-regulatory (e.g. IL-10, IL-4 and transforming growth factor-\(\beta\)) cytokines released by activated T helper1, T helper17 or regulatory lymphocytes. There is convincing evidence that this inflammatory cascade is driven by the GI microbiota. For example, animal models of inflammatory bowel disease reared in germ-free conditions do not develop GI inflammation until they are transferred to non-sterile conditions or until they are artificially colonised with bacteria\(^{(58)}\). Similar observations have been described in human subjects, where surgical diversion of the faecal stream away from the site of inflammation results in disease remission in the majority of patients\(^{(59)}\). More recently, the identification of Crohn’s disease susceptibility loci/gens also implicate the GI microbiota in its pathogenesis. For example, mutations in the caspase activating recruitment domain 15 gene, which is involved in bacterial recognition, increase the risk of developing Crohn’s disease 38-fold\(^{(60)}\), while mutations in genes responsible for the processing of intracellular bacteria through autophagy have also been implicated\(^{(61)}\).

Numerous studies have demonstrated alterations in many genera/species of the GI microbiota in Crohn’s disease compared with healthy controls. This ‘dysbiosis’ has been linked with some aspects of disease behaviour, including the presence of ileal disease\(^{(62)}\) and fistulizing disease\(^{(63)}\). Meanwhile, in a study of over 100 patients, smoking, an environmental risk factor for developing Crohn’s disease and for the severity of disease course, was associated with higher bacteroides\(^{(64)}\). Clinically relevant aspects of the ‘dysbiosis’ include lower luminal bifidobacteria\(^{(65,66)}\), where some species have been shown to stimulate dendritic cell IL-10 production in vitro\(^{(67)}\), where greater numbers are associated with higher mucosal IL-10+ dendritic cells in patients with Crohn’s disease\(^{(68)}\), indicating that dendritic cell function might be influenced by composition of the commensal microbiota. Furthermore, lower concentrations of \(F.\ prausnitzii\) have also been reported in Crohn’s disease which is relevant as higher numbers of this species are associated with longer post-operative disease maintenance, thought to be due to its immuno-regulatory capacity in reducing IL-12 and interferon-\(\gamma\) and stimulating IL-10 secretion\(^{(69)}\).

Prebiotics have been shown to stimulate faecal and mucosal bifidobacteria\(^{(10)}\) and \(F.\ prausnitzii\)\(^{(70)}\) in healthy people, while acetate and propionate increase immuno-regulatory IL-10 production\(^{(71)}\). Consequently, prebiotics have been investigated as a potential therapeutic target for Crohn’s disease\(^{(72)}\). Many animal studies have demonstrated the effectiveness of prebiotics in preventing and treating models of inflammatory bowel disease, although these results often differ depending upon the compound used (e.g. inulin and fructo-oligosaccharide)\(^{(73)}\). In human subjects, a number of studies have investigated the combined use of probiotic and prebiotic combinations\(^{(72)}\), but few have investigated the effect of prebiotics alone (Table 2).

The first was a pilot study of just ten patients with active Crohn’s disease consuming 15 g/d oligofructose/inulin that appeared to improve disease activity alongside increasing luminal bifidobacteria and stimulating IL-10+ dendritic cells and Toll-like receptor-2 expression\(^{(74)}\). Since these promising, but preliminary findings, two large randomised controlled trials have been published\(^{(75,76)}\). Neither demonstrated an impact of oligofructose/inulin at doses of 15 g/d\(^{(75)}\) or 20 g/d\(^{(76)}\) on Crohn’s disease activity; indeed both studies showed greater withdrawal in the prebiotic groups. Furthermore, neither of them resulted in higher bifidobacteria or \(F.\ prausnitzii\) in the prebiotic groups compared with placebo. Interestingly, one study showed that those patients who did experience an increase in bifidobacteria during prebiotic consumption had less severe disease, as evidenced by lower Crohn’s disease activity index and lower faecal calprotectin\(^{(75)}\). This perhaps suggests that the prebiotic effect may be most pronounced at lower levels of inflammation, highlighting a need for studies investigating the role of prebiotics in disease maintenance. Preliminary studies are also underway to investigate the role of prebiotics in the prevention of Crohn’s disease in those at elevated genetic risk\(^{(77)}\).

Given the lack of success of prebiotics in treating active Crohn’s disease, alternative approaches to successfully modifying the microbiota have been investigated. Few patients with Crohn’s disease (<5%) have ever used prebiotics to manage their disease, whereas many (>40%) have trialled probiotics\(^{(78)}\). A small number of clinical trials of probiotics have been undertaken, but a recent meta-analysis has shown no effects for the use of \(Lactobacillus\ rhamnosus\) GG or \(L.\ johnsonii\) for preventing endoscopic recurrence in inactive Crohn’s disease\(^{(79)}\). There is increasing interest in the use of faecal microbiota transplantation, which has been undertaken by a small number of institutions for many years, despite little robust research evidence. A recent systematic review failed
Table 2. Clinical trials of prebiotic supplementation in patients with Crohn’s disease

<table>
<thead>
<tr>
<th>Study details</th>
<th>Intervention</th>
<th>Microbiota findings</th>
<th>Immunological findings</th>
<th>Clinical findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncontrolled trial</td>
<td>Ten patients with active Crohn’s disease</td>
<td>Oligofructose/inulin (15 g/d)</td>
<td>Higher faecal bifidobacteria compared with baseline.</td>
<td>No difference between groups in disease activity, even in the prebiotic group compared with control (P = 0.07).</td>
</tr>
<tr>
<td>Randomised, double-blind trial</td>
<td>Forty patients with active Crohn’s disease</td>
<td>Oligofructose/inulin (15 g/d)</td>
<td>No difference between groups in any microbiota measured (including some bifidobacteria species), although increase in B. longum within the prebiotic group was measured.</td>
<td>Not measured</td>
</tr>
</tbody>
</table>
### Table 3. Clinical trials of prebiotic supplementation in patients with IBS

<table>
<thead>
<tr>
<th>Study details</th>
<th>Intervention</th>
<th>Microbiota findings</th>
<th>Microbiota findings</th>
<th>Clinical findings</th>
<th>Clinical findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hunter et al.</strong> (89)</td>
<td>(1) Oligofructose (6 g/d)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>Randomised, double-blind,</td>
</tr>
<tr>
<td></td>
<td>(2) Sucrose (3 g/d)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>Forty-one patients with IBS</td>
</tr>
<tr>
<td><strong>Olesen et al.</strong> (90)</td>
<td>(1) Fructo-oligosaccharide (20 g/d)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>Randomised, double-blind trial</td>
</tr>
<tr>
<td></td>
<td>(2) Placebo (20 g/d)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>Ninety-six patients with IBS</td>
</tr>
<tr>
<td><strong>Painieux et al.</strong> (91)</td>
<td>(1) Fructo-oligosaccharide (5 g/d)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>Randomised, double-blind trial</td>
</tr>
<tr>
<td></td>
<td>(2) Placebo (5 g/d)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>No difference between groups in stool weight, symptoms scores or whole gut transit time</td>
<td>Fifty patients with functional diarrhoea</td>
</tr>
<tr>
<td><strong>Silke et al.</strong> (92)</td>
<td>(1) Placebo followed by low dose GOS (3.5 g/d)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>Lower bifidobacteria in the low dose and high dose prebiotic group compared with placebo</td>
<td>Lower bifidobacteria in the low dose and high dose prebiotic group compared with placebo</td>
<td>Randomised, double-blind, cross-over trial</td>
</tr>
<tr>
<td></td>
<td>(2) Placebo followed by high dose GOS (7 g/d)</td>
<td>Not measured</td>
<td>Not measured</td>
<td>Lower bifidobacteria in the low dose and high dose prebiotic group compared with placebo</td>
<td>Lower bifidobacteria in the low dose and high dose prebiotic group compared with placebo</td>
<td>Forty-four patients with IBS</td>
</tr>
<tr>
<td></td>
<td>(3) Placebo followed by placebo</td>
<td>Not measured</td>
<td>Not measured</td>
<td>Lower bifidobacteria in the low dose and high dose prebiotic group compared with placebo</td>
<td>Lower bifidobacteria in the low dose and high dose prebiotic group compared with placebo</td>
<td></td>
</tr>
</tbody>
</table>

**IBS, irritable bowel syndrome; GOS, galacto-oligosaccharides.**

Bifidobacteria in diarrhoea-predominant IBS, has led to a small number of studies investigating prebiotics in its management (88). The four major studies have used a variety of prebiotics (oligofructose, fructo-oligosaccharide and GOS), in varying doses (3.5–20 g/d) and for varying durations (4–12 weeks) (89–92) (Table 3). Two trials, one using oligofructose (6 g/d) (89) and one using fructo-oligosaccharide (20 g/d) (90) found no significant impact on symptoms at the study endpoints, although in the latter high dose study, prebiotics actually worsened symptoms at the study mid-point (90). Two studies have demonstrated symptom improvement, with fructo-oligosaccharide (5 g/d) lowering composite symptom score (91) and trans-GOS (3.5 g/d) lowering flatulence and bloating and improving global symptom relief (92). However, in the latter study patients randomised to a higher dose of trans-GOS (7 g/d) reported higher composite symptom scores (92) (Table 3).

These data would suggest that both the type and dose of prebiotic is important in determining any clinical benefit in IBS, with some evidence that higher doses may have a negative impact on symptoms. High doses of fermentable carbohydrates can stimulate colonic gas production, which might increase flatulence and which in the context of visceral hypersensitivity might also induce abdominal discomfort and pain. In a recent study, a diet high in fermentable carbohydrates was shown to increase breath hydrogen in both fifteen patients with IBS and fifteen healthy controls (93). This was associated with an increase in abdominal pain, bloating and flatulence in patients with IBS, but only in flatulence in the healthy controls (93). A study in ileostomists has shown that diets high in fermentable carbohydrates can increase water delivery into the ileum, thus potentially contributing to the generation of diarrhoea (94).

Indeed, recent research has actually focused on restricting fermentable carbohydrates (fermentable oligo-, di, mono-saccharides and polyols) in IBS. There is now evidence for the use of the so-called ‘Low FODMAP diet’ from both non-randomised (95) and randomised trials (96). In the latter study of forty-one patients with IBS, those following a fermentable carbohydrate restricted diet were more likely to report adequate control of symptoms compared with controls (68% v. 23%; P = 0.005). However, this diet also reduced luminal bifidobacteria, which is hypothesised to be the result of restricting dietary prebiotic intake (96).

In contrast with both prebiotics and the low FODMAP diet, there are many clinical trials investigating the use of probiotics in the management of IBS. A recent Rome Foundation group report identified thirty-two randomised controlled trials of probiotics in IBS (97). At least six systematic reviews have been published on probiotics in IBS, and these have been summarised elsewhere (88). Most of the meta-analyses indicate a beneficial impact of probiotics on global symptoms, abdominal pain and flatulence, whereas the impact on bloating is equivocal. Based upon the evidence described here, recent guidelines have recommended the use of specific strains of probiotics, and the use of the low FODMAP diet in the management of IBS (98). The use of prebiotics in IBS should therefore be restricted to only
those compounds and doses for which there is supporting evidence.

Conclusion

The interaction between dietary intake and the microbiota in healthy people has been recognised for many years. However, evidence of the interaction between prebiotics, the GI microbiota and digestive disorders is now emerging, in part due to the development of more robust approaches to examine dietary intake, complex microbial ecosystems and disease outcomes. Unlike healthy human subjects, patients experience a number of issues that may alter their microbiota (disease, antibiotics and inflammation) and the use of microbiota modifying therapies, such as prebiotics, may not elicit the same effects in patients as they do in healthy people. The interaction between dietary intake, the microbiota and GI disease is emerging as an exciting area requiring research and application through multidisciplinary collaboration between experts in dietetics, microbiology and gastroenterology.

Acknowledgements

Many expert researchers and clinicians contributed to the research reviewed in this manuscript, whose collaboration is gratefully acknowledged. Particular thanks go to Professor Pat Judd (University of Central Lancashire), Dr Moira Taylor (University of Nottingham), Professor Victor Preedy, Professor Peter Emery, Dr Charlotte Hedin, Dr Gareth Parkes, Dr Jane Benjamin (King’s College London), Dr Hazreen Abdul Majid (University of Malaya), Dr James Lindsay (Barts Health NHS Trust), Dr Andrew Stagg (Queen Mary, University of London), Professor Alastair Forbes (University College London), Dr Ailsa Hart (St Marks Hospital), Dr Jeremy Sanderson, Dr Miranda Lomer, Heidi Staudacher and Dr Peter Irving (Guy’s and St Thomas’ NHS Foundation Trust and King’s College London).

K. W. has previously or currently received research funding, speaker’s honoraria or consulting fees from a range of research and charitable bodies, including the Broad Medical Research Program, British Dietetic Association, Core, Crohn’s and Colitis UK, Healthcare Quality Improvement Partnership and National Institute of Health Research, as well as industry bodies including the Californian Dried Prune Board, Danone, Dr Schar, Nestle, Nutricia, Novartis and Yakult. None of these funding bodies contributed to the writing of this manuscript.

References


64. Benjamin JL, Hedin CRH, Koutsoumpas A et al. (2012) Smokers with active Crohn’s disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 18, 1092–1100.

